Patrick Kee
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Patrick Kee has a total of 55 co-authors. Here are the top co-authors by number of shared publications:
David D. McPherson
Department of Internal Medicine, The University of Texas Health Science Center at Houston, Houston, TX, USA
4 shared publications- Delia Danila
Graduate School of Biomedical Sciences, Baylor College of Medicine, Houston, TX 77030, USA
3 shared publications - Susan T. Laing
Division of Cardiology, Department of Internal Medicine, University of Texas Health Science Center at Houston, Houston, Texas, USA
3 shared publications Deborah Vela
Cardiovascular Pathology Research Department, Texas Heart Institute, Houston, TX, USA
2 shared publications- Melanie R. Moody
Division of Cardiology, Department of Internal Medicine, McGovern Medical School, The University of Texas Health Science Center at Houston, Houston, TX 77030, USA
2 shared publications - Melvin Earl Klegerman
Department of Internal Medicine, Division of Cardiovascular Medicine, University of Texas Health Science Center at Houston, Houston, TX 77054, USA
2 shared publications
Latest Publications
- 9 August 2022
- Published by Taylor & Francis in Journal of Drug Targeting
- Vol. 31 (1) , 109-118
Demonstration of ultrasound-mediated therapeutic delivery of fibrin-targeted pioglitazone-loaded echogenic liposomes into the arterial bed for attenuation of peri-stent restenosis
Peri-stent restenosis following stent implantation is a major clinical problem. We have previously demonstrated that ultrasound-facilitated liposomal delivery of pioglitazone (PGN) to the arterial wall attenuated in-stent restenosis. To evaluate ultrasound mediated arterial delivery, in Yucatan miniswine, balloon inflations were performed in the carotid and subclavian arteries to simulate stent implantation and induce fibrin formation. The fibrin-binding peptide, GPRPPGGGC, was conjugated to echogenic liposomes (ELIP) containing dinitrophenyl-L-alanine-labelled pioglitazone (DNP-PGN) for targeting purposes. After pre-treating the arteries with nitroglycerine, fibrin-binding peptide-conjugated PGN-loaded ELIP (PAFb-DNP-PGN-ELIP also termed atheroglitatide) were delivered to the injured arteries via an endovascular catheter with an ultrasound core, either with or without ultrasound application (EKOSTM Endovascular System, Boston Scientific). In arteries treated with atheroglitatide, there was substantial delivery of PGN into the superficial layers (5 µm from the lumen) of the arteries with and without ultrasound, [(1951.17 relative fluorescence units (RFU) vs. 1901.17 RFU; P-value = 0.939)]. With ultrasound activation there was increased penetration of PGN into the deeper arterial layers (up to 35 µm from the lumen) [(13195.25 RFU vs. 7681.00 RFU; P-value = 0.005)]. These pre-clinical data demonstrate ultrasound mediated therapeutic vascular delivery to deeper layers of the injured arterial wall. This model has the potential to reduce peri- stent restenosis.
- 9 August 2022
- Published by Taylor & Francis in Journal of Drug Targeting
- Vol. 31 (1) , 109-118
Demonstration of ultrasound-mediated therapeutic delivery of fibrin-targeted pioglitazone-loaded echogenic liposomes into the arterial bed for attenuation of peri-stent restenosis
Peri-stent restenosis following stent implantation is a major clinical problem. We have previously demonstrated that ultrasound-facilitated liposomal delivery of pioglitazone (PGN) to the arterial wall attenuated in-stent restenosis. To evaluate ultrasound mediated arterial delivery, in Yucatan miniswine, balloon inflations were performed in the carotid and subclavian arteries to simulate stent implantation and induce fibrin formation. The fibrin-binding peptide, GPRPPGGGC, was conjugated to echogenic liposomes (ELIP) containing dinitrophenyl-L-alanine-labelled pioglitazone (DNP-PGN) for targeting purposes. After pre-treating the arteries with nitroglycerine, fibrin-binding peptide-conjugated PGN-loaded ELIP (PAFb-DNP-PGN-ELIP also termed atheroglitatide) were delivered to the injured arteries via an endovascular catheter with an ultrasound core, either with or without ultrasound application (EKOSTM Endovascular System, Boston Scientific). In arteries treated with atheroglitatide, there was substantial delivery of PGN into the superficial layers (5 µm from the lumen) of the arteries with and without ultrasound, [(1951.17 relative fluorescence units (RFU) vs. 1901.17 RFU; P-value = 0.939)]. With ultrasound activation there was increased penetration of PGN into the deeper arterial layers (up to 35 µm from the lumen) [(13195.25 RFU vs. 7681.00 RFU; P-value = 0.005)]. These pre-clinical data demonstrate ultrasound mediated therapeutic vascular delivery to deeper layers of the injured arterial wall. This model has the potential to reduce peri- stent restenosis.
- Open Access
- 1 January 2019
- Published by XMLink in Immune Network
- Vol. 19 (6) , e41
A Critical Role of PCSK9 in Mediating IL-17-Producing T Cell Responses in Hyperlipidemia
Kim YU, et al. Immune Netw. 2019 Dec;19(6):e41. https://doi.org/10.4110/in.2019.19.e41
- 1 January 2019
- Published by XMLink in Immune Network
- Vol. 19 (6) , e41
Open AccessA Critical Role of PCSK9 in Mediating IL-17-Producing T Cell Responses in Hyperlipidemia
Kim YU, et al. Immune Netw. 2019 Dec;19(6):e41. https://doi.org/10.4110/in.2019.19.e41
- Open Access
- 24 August 2016
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 17 (9) , 1383
CTHRSSVVC Peptide as a Possible Early Molecular Imaging Target for Atherosclerosis
The purpose of our work was to select phages displaying peptides capable of binding to vascular markers present in human atheroma, and validate their capacity to target the vascular markers in vitro and in low-density lipoprotein receptor knockout (LDLr−/−) mouse model of atherosclerosis. By peptide fingerprinting on human atherosclerotic tissues, we selected and isolated four different peptides sequences, which bind to atherosclerotic lesions and share significant similarity to known human proteins with prominent roles in atherosclerosis. The CTHRSSVVC-phage peptide displayed the strongest reactivity with human carotid atherosclerotic lesions (p < 0.05), when compared to tissues from normal carotid arteries. This peptide sequence shares similarity to a sequence present in the fifth scavenger receptor cysteine-rich (SRCR) domain of CD163, which appeared to bind to CD163, and subsequently, was internalized by macrophages. Moreover, the CTHRSSVVC-phage targets atherosclerotic lesions of a low-density lipoprotein receptor knockout (LDLr−/−) mouse model of atherosclerosis in vivo to High-Fat diet group versus Control group. Tetraazacyclododecane-1,4,7,10-tetraacetic acid-CTHRSSVVC peptide (DOTA-CTHRSSVVC) was synthesized and labeled with 111InCl3 in >95% yield as determined by high performance liquid chromatography (HPLC), to validate the binding of the peptide in atherosclerotic plaque specimens. The results supported our hypothesis that CTHRSSVVC peptide has a remarkable sequence for the development of theranostics approaches in the treatment of atherosclerosis and other diseases.
- 24 August 2016
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 17 (9) , 1383
Open AccessCTHRSSVVC Peptide as a Possible Early Molecular Imaging Target for Atherosclerosis
The purpose of our work was to select phages displaying peptides capable of binding to vascular markers present in human atheroma, and validate their capacity to target the vascular markers in vitro and in low-density lipoprotein receptor knockout (LDLr−/−) mouse model of atherosclerosis. By peptide fingerprinting on human atherosclerotic tissues, we selected and isolated four different peptides sequences, which bind to atherosclerotic lesions and share significant similarity to known human proteins with prominent roles in atherosclerosis. The CTHRSSVVC-phage peptide displayed the strongest reactivity with human carotid atherosclerotic lesions (p < 0.05), when compared to tissues from normal carotid arteries. This peptide sequence shares similarity to a sequence present in the fifth scavenger receptor cysteine-rich (SRCR) domain of CD163, which appeared to bind to CD163, and subsequently, was internalized by macrophages. Moreover, the CTHRSSVVC-phage targets atherosclerotic lesions of a low-density lipoprotein receptor knockout (LDLr−/−) mouse model of atherosclerosis in vivo to High-Fat diet group versus Control group. Tetraazacyclododecane-1,4,7,10-tetraacetic acid-CTHRSSVVC peptide (DOTA-CTHRSSVVC) was synthesized and labeled with 111InCl3 in >95% yield as determined by high performance liquid chromatography (HPLC), to validate the binding of the peptide in atherosclerotic plaque specimens. The results supported our hypothesis that CTHRSSVVC peptide has a remarkable sequence for the development of theranostics approaches in the treatment of atherosclerosis and other diseases.
- 10 October 2014
- Published by Springer Nature in Molecular Imaging and Biology
- Vol. 17 (3) , 328-336
Noninvasive Detection of Macrophages in Atheroma Using a Radiocontrast-Loaded Phosphatidylserine-Containing Liposomal Contrast Agent for Computed Tomography
Macrophage plays an important role in plaque destabilization in atherosclerosis. By harnessing the affinity of macrophages to certain phospholipid species, a liposomal contrast agent containing phosphatidylserine (PS) and X-ray computed tomographic (CT) contrast agent was prepared and evaluated for CT imaging of plaque-associated macrophages in rabbit models of atherosclerosis.
- 10 October 2014
- Published by Springer Nature in Molecular Imaging and Biology
- Vol. 17 (3) , 328-336
Noninvasive Detection of Macrophages in Atheroma Using a Radiocontrast-Loaded Phosphatidylserine-Containing Liposomal Contrast Agent for Computed Tomography
Macrophage plays an important role in plaque destabilization in atherosclerosis. By harnessing the affinity of macrophages to certain phospholipid species, a liposomal contrast agent containing phosphatidylserine (PS) and X-ray computed tomographic (CT) contrast agent was prepared and evaluated for CT imaging of plaque-associated macrophages in rabbit models of atherosclerosis.
- 1 June 2014
- Published by Elsevier in Ultrasound in Medicine & Biology
- Vol. 40 (6) , 1167-1176
Nitric Oxide Pretreatment Enhances Atheroma Component Highlighting in Vivo with Intercellular Adhesion Molecule-1-Targeted Echogenic Liposomes
- 1 June 2014
- Published by Elsevier in Ultrasound in Medicine & Biology
- Vol. 40 (6) , 1167-1176
Nitric Oxide Pretreatment Enhances Atheroma Component Highlighting in Vivo with Intercellular Adhesion Molecule-1-Targeted Echogenic Liposomes
- 1 February 2013
- Published by Elsevier in JACC: Cardiovascular Imaging
- Vol. 6 (2) , 263-268
Evaluation of Mitral Valve Dynamics
- 1 February 2013
- Published by Elsevier in JACC: Cardiovascular Imaging
- Vol. 6 (2) , 263-268
Evaluation of Mitral Valve Dynamics
- 11 November 2010
- Published by Springer Nature
- p. 723-747
Molecular Imaging of Atherosclerosis
- 3 July 2010
- Published by Springer Nature in Current Cardiovascular Risk Reports
- Vol. 4 (5) , 332-339
Targeted Molecular Imaging to Detect Vascular Disease
- 3 July 2010
- Published by Springer Nature in Current Cardiovascular Risk Reports
- Vol. 4 (5) , 332-339
Targeted Molecular Imaging to Detect Vascular Disease
- 15 May 2008
- Published by Springer Nature in Current Atherosclerosis Reports
- Vol. 10 (3) , 260-271
Experimental models investigating the inflammatory basis of atherosclerosis
Inflammation is considered an important aspect in the development of atherosclerosis. Genetic manipulations of animal models susceptible to atherosclerosis have unraveled the contribution of various inflammatory pathways implicated in the development of atherosclerosis. These inflammatory pathways not only lead to the recruitment and entry of inflammatory cells into the arterial wall, they also modify the morphology and composition of atherosclerotic plaques. Certain inflammatory pathways, such as P-selectin, intercellular adhesion molecule-1, and vascular cell adhesion molecule-1, appear to play an important role in lesion initiation, whereas others, such as interleukin-10 and CD40/CD40 ligand, seem to contribute to lesion progression and morphologic changes. An understanding of these pathways will allow the development of new strategies in the management of atherosclerosis. This review provides a roadmap for better utilization of these models in atherosclerosis research.
- 15 May 2008
- Published by Springer Nature in Current Atherosclerosis Reports
- Vol. 10 (3) , 260-271
Experimental models investigating the inflammatory basis of atherosclerosis
Inflammation is considered an important aspect in the development of atherosclerosis. Genetic manipulations of animal models susceptible to atherosclerosis have unraveled the contribution of various inflammatory pathways implicated in the development of atherosclerosis. These inflammatory pathways not only lead to the recruitment and entry of inflammatory cells into the arterial wall, they also modify the morphology and composition of atherosclerotic plaques. Certain inflammatory pathways, such as P-selectin, intercellular adhesion molecule-1, and vascular cell adhesion molecule-1, appear to play an important role in lesion initiation, whereas others, such as interleukin-10 and CD40/CD40 ligand, seem to contribute to lesion progression and morphologic changes. An understanding of these pathways will allow the development of new strategies in the management of atherosclerosis. This review provides a roadmap for better utilization of these models in atherosclerosis research.